BMB-101

Bright Minds Biosciences announced that BMB-101 demonstrated complete elimination of drop attacks in the DBA/2 mouse model, a highly predictive model for sudden unexpected death in epilepsy (SUDEP).

Capsida Biotherapeutics has received FDA IND clearance for CAP-002, the first intravenously administered gene therapy that crosses the blood-brain barrier while avoiding off-target tissues for STXBP1-DEE.

Analyst Yasmeen Rahimi has initiated coverage of Bright Minds Biosciences with a Buy rating, highlighting the potential of their lead compound BMB-101 for treating drug-resistant epilepsies. The G-protein biased 5-HT2C agonist has shown promising safety profiles in Phase 1 trials, with Phase 2 BREAKTHROUGH study results expected in late 2025.

Bright Minds Biosciences has appointed Stephen D. Collins, M.D., Ph.D., as Chief Medical Officer, effective immediately, to spearhead the development of novel CNS therapies.

Bright Minds Biosciences has appointed Stephen Collins, M.D., Ph.D., as Chief Medical Officer, effective immediately, to lead clinical development efforts.